Free Trial
NASDAQ:COLL

Collegium Pharmaceutical Q3 2025 Earnings Report

Collegium Pharmaceutical logo
$33.21 +0.08 (+0.24%)
Closing price 10/9/2025 04:00 PM Eastern
Extended Trading
$33.54 +0.33 (+0.99%)
As of 10/9/2025 06:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Collegium Pharmaceutical EPS Results

Actual EPS
N/A
Consensus EPS
$1.89
Beat/Miss
N/A
One Year Ago EPS
N/A

Collegium Pharmaceutical Revenue Results

Actual Revenue
N/A
Expected Revenue
$191.25 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Collegium Pharmaceutical Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Thursday, November 6, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

Collegium Pharmaceutical Earnings Headlines

Collegium Pharmaceutical, Inc. (COLL): A Bull Case Theory
Elon calling
Elon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corporate history. Tesla insiders are preparing for a dramatic new product launch – not driverless cars – that could change everything. You're running out of time to prepare.tc pixel
See More Collegium Pharmaceutical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Collegium Pharmaceutical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Collegium Pharmaceutical and other key companies, straight to your email.

About Collegium Pharmaceutical

Collegium Pharmaceutical (NASDAQ:COLL) is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S. Food and Drug Administration (FDA) in 2016, and Apadaz® (hydrocodone bitartrate and acetaminophen) tablets. Collegium also markets Rybix® ODT (oxycodone), an orally disintegrating tablet, and has rights to the fentanyl transdermal system ONSOLIS® under a distribution agreement. These products are supported by a dedicated commercial organization and are primarily available in the United States.

Headquartered in Wilmington, North Carolina, Collegium maintains research, development and manufacturing operations, including a facility in Richmond, Virginia. Since its incorporation in 2013, the company has expanded its product portfolio and pursued a pipeline of additional abuse-deterrent drug candidates, seeking to address unmet needs in both acute and chronic pain treatment.

Collegium is led by a management team with experience in specialty pharmaceuticals and regulatory affairs. Michael Thomas serves as President and Chief Executive Officer, guiding the company’s strategic direction and commercial growth initiatives. Under this leadership, Collegium continues to advance its mission of improving patient safety and outcomes through innovative drug delivery technologies.

View Collegium Pharmaceutical Profile

More Earnings Resources from MarketBeat